Products
BladderLight™: transforming urine cytology for the diagnosis and management of bladder cancer
Bladder cancer: the clinical background
Bladder cancer is a common cancer, with over 429,000 new cases diagnosed globally in 2012, and it is an expensive cancer, costing the UK alone over £50 million per year. Currently, the gold standard diagnosis and management tool for bladder cancer is cystoscopy, which is expensive, uncomfortable and carries a risk of infection. Because of the high recurrence rate of bladder cancer (up to 35% in the first 3 years), these shortcomings are exacerbated by the need for repeated surveillance, which may extend to quarterly cystoscopies for 1-2 years post-surgery, every 6 months in year 3-4, and annually thereafter.
The Cytosystems’ alternative: BladderLight™
Compared to cystoscopy, BladderLight™ is:
- cost-effective
- non-invasive
- more comfortable for patients
- free from risk of infection
- highly accurate.
BladderLight™ employs the latest diagnostic technologies to create a full stratification package:
- improved cell collection,
- sensitive and specific molecular marker, reducing the level of false positives that would be present in a molecular-only approach
- whole-cell approach
- digitized analysis
BladderLight™ is easily integrated into current clinical practice, and significantly enhances the capability of cytology to match the standards of accuracy of current cystoscopy.
Clinical benefits
- User-friendly cell collection device that rapidly preserve the cells of interest
- Clinically verified assay based on established universal MCM biomarker technology
- Whole-cell approach for improved clinical decisions by reducing the level of false positives by not relying solely on a molecular approach.
- Significantly cost-effective procedures
- Highly accurate diagnosis, with high specificity and sensitivity
- Readily integrates into current clinical practice
- Non-invasive, eliminating risk of infection for patients
- Suitable for surveillance and monitoring of disease
- Automated analysis systems are more time-efficient for cytopathologists.
